Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 2/20 | 0.64 |
| ▸ | NR2E3 | Q9Y5X4 | 2/20 | 0.64 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | LIMK1 | P53667 | 8/20 | 0.59 |
| ▸ | CLK1 | P49759 | 3/20 | 0.54 |
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.47 |
| ▸ | ACACA | Q13085 | 1/20 | 0.46 |
| ▸ | CDC7 | O00311 | 3/20 | 0.46 |
| ▸ | DBF4 | Q9UBU7 | 3/20 | 0.46 |
| ▸ | KDR | P35968 | 2/20 | 0.46 |
| ▸ | PLK4 | O00444 | 1/20 | 0.46 |
| ▸ | IKBKB | O14920 | 1/20 | 0.46 |
| ▸ | AURKA | O14965 | 1/20 | 0.46 |
| ▸ | CHUK | O15111 | 1/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.46 |
| ▸ | FYN | P06241 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4899938 | 0.90 | LIMK1 (0.66) | PPARGNR2E3NCOR2KMT2ALIMK1 | |
| SCHEMBL4899880 | 0.88 | KDM4E (0.62) | PPARGNR2E3NCOR2KMT2ALIMK1 | |
| SCHEMBL4900157 | 0.86 | HPGD (0.62) | PPARGNR2E3NCOR2KMT2ALIMK1 | |
| SCHEMBL4900523 | 0.83 | MAPT (0.60) | PPARGNR2E3NCOR2KMT2ALIMK1 | |
| SCHEMBL4899965 | 0.82 | CDC7 (0.58) | PPARGNR2E3NCOR2KMT2ALIMK1 | |
| SCHEMBL4905558 | 0.81 | CDC7 (0.66) | LIMK1CLK1KDM4ECDC7DBF4 | |
| SCHEMBL259291 | 0.81 | CDC7 (0.66) | PPARGNR2E3NCOR2KMT2ALIMK1 | |
| SCHEMBL4894356 | 0.78 | HPGD (0.58) | KMT2ALIMK1CLK1KDM4EPOLB | |
| SCHEMBL4899003 | 0.77 | MEN1 (0.59) | KMT2ALIMK1CLK1KDM4EPOLB | |
| SCHEMBL4899997 | 0.77 | MAPT (0.50) | KMT2ALIMK1ACHEKDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080008720-A1 | Substituted Tricyclic Heterocycles and their Uses | CYWIN CHARLES L | 2008-01-10 | — | — | US | disclosed |
| US-7291733-B2 | Substituted tricyclic heterocycles and their uses | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2007-11-06 | — | — | US | disclosed |
| EP-1673374-A2 | SUBSTITUTED TRICYCLIC HETEROCYCLES AND THEIR USES | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2006-06-28 | — | — | EP | disclosed |
| US-20050101601-A1 | Substituted tricyclic heterocycles and their uses | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-05-12 | — | — | US | disclosed |
| WO-2005035537-A2 | SUBSTITUTED TRICYCLIC HETEROCYCLES AND THEIR USES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101601-A1 | Substituted tricyclic heterocycles and their uses | LTC4S, NQO1, CBR3 | PPARG 550/4885NR2E3 1485/4885NCOR2 522/4885 |
| US-20080008720-A1 | Substituted Tricyclic Heterocycles and their Uses | LTC4S, NQO1, CBR3 | PPARG 550/4885NR2E3 1485/4885NCOR2 522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.